ASH13CONTENT VALIDATION AND DISCLOSURES FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Non-Hodgkin Lymphoma Faculty Michele E Ghielmini, MD, PhD Advisory Committee: Celgene Corporation, GlaxoSmithKline; Consulting Agreement: Millennium: The Takeda Oncology Company; Speakers Bureau: Mundipharma International Limited, Pfizer Inc, Roche Laboratories Steven M Horwitz, MD Consulting Agreements: Allos Therapeutics, Bristol-Myers Squibb Company, Celgene Corporation, Genzyme Corporation, Janssen Pharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Kyowa Hakko Kirin Co Ltd, Millennium: The Takeda Oncology Company, Seattle Genetics; Contracted Research: Allos Therapeutics, Celgene Corporation, Infinity Pharmaceuticals Inc, Kyowa Hakko Kirin Co Ltd, Millennium: The Takeda Oncology Company, Seattle Genetics, Spectrum Pharmaceuticals Inc. Brad S Kahl, MD Advisory Committee: Celgene Corporation, Cephalon Inc, Genentech Laurie H Sehn, MD, MPH Consulting Agreements: Amgen Inc, Celgene Corporation, Cephalon Inc, Genentech BioOncology, Gilead Sciences Inc, GlaxoSmithKline, Lundbeck Canada Inc, Roche Laboratories Inc; Contracted Research: Lundbeck Canada Inc, Roche Laboratories Inc. Mitchell R Smith, MD, PhD Advisory Committee: Celgene Corporation, Cephalon Inc; Speakers Bureau: Allos Therapeutics, Spectrum Pharmaceuticals Inc. Multiple Myeloma Faculty William I Bensinger, MD Advisory Committee: Celgene Corporation, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc, Sanofi; Consulting Agreement: Celgene Corporation; Contracted Research: Celgene Corporation, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc; Speakers Bureau: Celgene Corporation. Meletios A Dimopoulos, MD Advisory Committee: Celgene Corporation, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc. Amrita Krishnan, MD Advisory Committee: Celgene Corporation, Onyx Pharmaceuticals Inc; Ownership Interest: Celgene Corporation; Speakers Bureau: Celgene Corporation, Genentech BioOncology, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc. Noopur Raje, MD Advisory Committee: Amgen Inc, Celgene Corporation; Consulting Agreements: Lilly, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc; Contracted Research: Acetylon Pharmaceuticals Inc, Amgen Inc, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation. A Keith Stewart, MBChB Advisory Committee: Amgen Inc, Celgene Corporation; Consulting Agreements: Celgene Corporation, Millennium: The Takeda Oncology Company; Contracted Research: Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc. This material may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors. This activity is supported by educational grants from Celgene Corporation, Genentech BioOncology/Biogen Idec, Lilly, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc and Teva Oncology. |